Cerebral toxoplasmosis and AIDS. Clinical, neuroradiological and immunological findings in 15 patients.
Cerebral toxoplasmosis is the most common cause of focal CNS disease complicating AIDS and its incidence ranges from 3% to 40% of such patients. This opportunistic infection is generally due to reactivation of chronic toxoplasmosis as a consequence of severe immune deficiency. We present the clinical, neuroradiological and immunological findings of 15 AIDS patients with cerebral toxoplasmosis. All patients had focal neurological signs. CT-scan (13 cases) and NMR (2 cases) showed single or multiple mass lesions and edema. Serum IgG anti-Toxoplasma antibodies were positive in 14 patients; CSF specific IgG were positive in 5 out of 7 studied patients, while serum and CSF specific IgM were negative in all subjects. The intrathecal synthesis of anti-Toxoplasma antibodies were high in all 7 patients. A presumptive diagnosis of cerebral toxoplasmosis is based on the focal cerebral signs and neuroradiological findings. It is more frequently confirmed by the improvement of the clinical and neuroradiological picture during the treatment with pyrimethamine-sulphadiazine or clindamycin.
Orefice
G
G
Second Neurologic Clinic, Medical School, Federico II University, Naples.
Carrieri
P B
PB
Chirianni
A
A
Rubino
S
S
Liuzzi
G
G
Napolitano
G
G
Rocco
A
A
D017088:AIDS-Related Opportunistic Infections / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000276:immunology / Q000469:parasitology*; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D001929:Brain Edema / Q000188:drug therapy / Q000209:etiology; D002981:Clindamycin / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D005990:Glycerol / Q000627:therapeutic use; D006429:Hemiplegia / Q000209:etiology; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D011739:Pyrimethamine / Q000627:therapeutic use; D011859:Radiography; D013411:Sulfadiazine / Q000627:therapeutic use; D014122:Toxoplasma / Q000276:immunology; D016781:Toxoplasmosis, Cerebral / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000276:immunology; D016896:Treatment Outcome
D000913:Antibodies, Protozoan; D013411:Sulfadiazine; D002981:Clindamycin; D003907:Dexamethasone; D005990:Glycerol; D002955:Leucovorin; D011739:Pyrimethamine